| Primary information |
|---|
| sequence ID | Seq_955 |
| Peptide sequence | AVPPNNSNAAEDDLPTVELQGVVPR |
| CancerPDF_ID | CancerPDF_ID99, CancerPDF_ID200, CancerPDF_ID1095, CancerPDF_ID2045, CancerPDF_ID9643, CancerPDF_ID12719, |
| PMID | 16896061,19728888,16395409,21136997,21533267,27058005 |
| Protein Name | Factor XIIIa,Coagulation factor XIIIA,Factor XIIIa,Coagulation factor XIII A chain,Coagulation factor XIII A chain,Coagulation factor XIII A chain |
| UniprotKB Entry Name | F13A_HUMAN,F13A_HUMAN,F13A_HUMAN,F13A_HUMAN,F13A_HUMAN,F13A_HUMAN |
| Fluid | Serum,Serum,Serum,Serum,Serum,Serum |
| M/Z | 2602.15,2602.3048,2602.15,2601.30346,868.08,2602.306 |
| Charge | 1,NA,1,1,3,NA |
| Mass (in Da) | 2602.3,NA,NA,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,LC-MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | NA,NA,NA,LC-ESI-MS,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,NA,less than 1 “5,NA,1.49,NA |
| CancerPDF_ID | CancerPDF_ID99, CancerPDF_ID200, CancerPDF_ID1095, CancerPDF_ID2045, CancerPDF_ID9643, CancerPDF_ID12719, |
| p-Value | 1.00E-05,less than 0.05,6.60E-10,NA,NA,"less than 0.001,0.632,0.408" |
| Software | MASCOT,MASCOT(v 2.0.04 for Windows),MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,Proteome Discoverer |
| Length | 23,23,23,23,23,23 |
| Cancer Type | Metastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy","Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Lung adenocarcinoma,Breast cancer |
| Database | NCBI refseq Protein Database,SwissProt Database (release 54.7),NCBI refseq Protein Database,SwissProt Database,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =2.84, 2.3 and 4.73 in prostate, bladder and breast cancer respectively",NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 0.47 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.04, Upregulated in BC vs healthy with 1.073 fold change" |
| Validation | Independent validation,Independent validation,Independent validation,Leave One out Cross validation,MRM-based validation of 19 candidates,NA |
| Sensitivity | 95% on independent dataset,1,97.5% for multiclass and 100 % for binary classification system on independent validation dataset,NA,NA,NA |
| Specificity | 95% on independent dataset,0.73,NA,NA,NA,NA |
| Accuracy | NA,0.86,97.5 % on validation dataset,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |